S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
$0.00
$0.00
$0.01
N/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$4.33
+18.6%
$3.75
$2.70
$11.82
$8.62M2.2643,414 shs254,345 shs
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
$0.58
$0.22
$2.40
$997K0.658.25 million shs1.89 million shs
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
$0.17
-5.7%
$4.22
$0.66
$10.77
$1.66M-1.237.68 million shs77,428 shs
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
$0.73
$0.52
$11.14
$3.19M-0.03197,480 shs77,500 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
0.00%0.00%0.00%0.00%-98.00%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
+2.24%-4.45%-7.12%+21.67%-68.56%
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
0.00%0.00%0.00%-56.07%-76.93%
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
+4.09%+3.90%+5.31%-28.10%-94.49%
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
0.00%0.00%0.00%0.00%-58.75%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/AN/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/A
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/AN/AN/AN/A
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$5.90M1.46N/AN/A$13.18 per share0.33
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/A$6.48 per shareN/A
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
$1.59M1.04N/AN/A$0.60 per share0.28
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
$10K0.00N/AN/A$4.29 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/A0.00N/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
-$6.53M-$6.23N/AN/A-110.64%-31.31%-29.32%5/1/2024 (Estimated)
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/A
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
-$12.33MN/AN/AN/A-776.76%-161.38%-83.58%N/A
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
-$26.86M-$92.36N/AN/AN/AN/A-496.57%-344.49%N/A

Latest OBLN, MDIT, RMED, NURO, and NVIV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/22/2024Q4 2023
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A-$1.43-$1.43-$1.43N/A$1.32 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/AN/A
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/AN/AN/AN/AN/A
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A
16.80
15.55
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/A
14.30
14.30
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/A
1.86
1.86
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
N/A
2.86
2.85

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
69N/AN/ANot Optionable
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
261.99 million1.84 millionNot Optionable
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
63.11 million3.03 millionNot Optionable
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
210.02 millionN/ANot Optionable
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
145.37 million4.37 millionNot Optionable

OBLN, MDIT, RMED, NURO, and NVIV Headlines

SourceHeadline
Dietary Interventions Reduce CVD Risk in RA and SpADietary Interventions Reduce CVD Risk in RA and SpA
ajmc.com - March 8 at 7:57 PM
Alert1 Medical Alert System Review: What Experts Say (2024)Alert1 Medical Alert System Review: What Experts Say (2024)
forbes.com - February 20 at 9:27 PM
Ra Medical Systems Inc.Ra Medical Systems Inc.
thestreet.com - February 15 at 10:42 AM
Catheter Precision Inc (VTAK)Catheter Precision Inc (VTAK)
investing.com - February 11 at 11:09 PM
VTAK Catheter Precision, Inc.VTAK Catheter Precision, Inc.
seekingalpha.com - January 19 at 6:41 PM
What Is The Life Expectancy Of Rheumatoid Arthritis? A Review By DoctorsWhat Is The Life Expectancy Of Rheumatoid Arthritis? A Review By Doctors
msn.com - January 7 at 11:58 PM
Catheter Precision Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-QCatheter Precision Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Q
finance.yahoo.com - August 25 at 6:53 PM
Reminder: Ra Medical Systems Announces Name and Ticker Symbol ChangesReminder: Ra Medical Systems Announces Name and Ticker Symbol Changes
finance.yahoo.com - August 17 at 9:15 AM
Ra Medical Systems, Inc.: Ra Medical Systems Announces Allowance of New Closure Device PatentRa Medical Systems, Inc.: Ra Medical Systems Announces Allowance of New Closure Device Patent
finanznachrichten.de - August 16 at 6:14 PM
Ra Medical Systems Announces Milestone Achievement for Electrophysiology DivisionRa Medical Systems Announces Milestone Achievement for Electrophysiology Division
finance.yahoo.com - August 7 at 12:14 PM
Ra Medical Systems, Inc.: Ra Medical Systems Announces Proposed Name and Ticker Symbol ChangesRa Medical Systems, Inc.: Ra Medical Systems Announces Proposed Name and Ticker Symbol Changes
finanznachrichten.de - August 2 at 8:13 AM
Ra Medical says demand is rising for its non-invasive electrophysiology mapping systemRa Medical says demand is rising for its non-invasive electrophysiology mapping system
massdevice.com - July 24 at 5:15 PM
Ra Medical Systems, Inc.: Ra Medical Systems Electrophysiology Division Has Increased Demand for its Non-invasive Mapping SystemRa Medical Systems, Inc.: Ra Medical System's Electrophysiology Division Has Increased Demand for its Non-invasive Mapping System
finanznachrichten.de - July 24 at 12:14 PM
Ra Medical System’s Electrophysiology Division Has Increased Demand for its Non-invasive Mapping SystemRa Medical System’s Electrophysiology Division Has Increased Demand for its Non-invasive Mapping System
finance.yahoo.com - July 24 at 12:14 PM
Ra Medical Systems, Inc.: RMEDs LockeT Device Utilized in Structural Heart ProceduresRa Medical Systems, Inc.: RMED's LockeT Device Utilized in Structural Heart Procedures
finanznachrichten.de - July 6 at 10:17 AM
RMEDs LockeT Device Utilized in Structural Heart ProceduresRMED's LockeT Device Utilized in Structural Heart Procedures
finance.yahoo.com - July 6 at 10:17 AM
Investing in Ra Medical Systems Inc (RMED): What You Must KnowInvesting in Ra Medical Systems Inc (RMED): What You Must Know
knoxdaily.com - July 5 at 6:18 PM
Ra Medical Systems, Inc.: RMEDs Electrophysiology Division Submits Data for CE Mark on LockeT Expects to Receive CE Mark in Third Quarter, 2023Ra Medical Systems, Inc.: RMED's Electrophysiology Division Submits Data for CE Mark on LockeT Expects to Receive CE Mark in Third Quarter, 2023
finanznachrichten.de - June 28 at 9:07 AM
RMEDs Electrophysiology Division Submits Data for CE Mark on LockeT Expects to Receive CE Mark in Third Quarter, 2023RMED's Electrophysiology Division Submits Data for CE Mark on LockeT Expects to Receive CE Mark in Third Quarter, 2023
finance.yahoo.com - June 28 at 9:07 AM
Ra Medical Systems, Inc.: Ra Medicals Electrophysiology Division Announces First Hospital to Complete 100 Procedures Using the VIVO SystemRa Medical Systems, Inc.: Ra Medical's Electrophysiology Division Announces First Hospital to Complete 100 Procedures Using the VIVO System
finanznachrichten.de - June 12 at 4:10 PM
Ra Medical’s Electrophysiology Division Announces First Hospital to Complete 100 Procedures Using the VIVO SystemRa Medical’s Electrophysiology Division Announces First Hospital to Complete 100 Procedures Using the VIVO System
finance.yahoo.com - June 12 at 4:10 PM
Medical Device Co. Completes Merger in Q1/23Medical Device Co. Completes Merger in Q1/23
investorideas.com - June 9 at 9:35 PM
Ra Medical Systems reports Q1 resultsRa Medical Systems reports Q1 results
msn.com - June 5 at 10:34 AM
Ra Medical Systems, Inc.: Ra Medical Systems Announces First Quarter ResultsRa Medical Systems, Inc.: Ra Medical Systems Announces First Quarter Results
finanznachrichten.de - June 2 at 9:16 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Medite Cancer Diagnostics logo

Medite Cancer Diagnostics

OTCMKTS:MDIT
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.
NeuroMetrix logo

NeuroMetrix

NASDAQ:NURO
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
InVivo Therapeutics logo

InVivo Therapeutics

NASDAQ:NVIV
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.
Obalon Therapeutics logo

Obalon Therapeutics

NASDAQ:OBLN
Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.
Ra Medical Systems logo

Ra Medical Systems

NYSE:RMED
Ra Medical Systems, Inc develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. Ra Medical Systems, Inc is based in Fort Mill, South Carolina.